HEALTH TRIAGE
Innovating the sector of technologies for cancer prevention.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | €10.0m | Seed | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 2 % | (4 %) | 27 % | (1 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20 %) | (30 %) | (36 %) | (62 %) | (70 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Health Triage S.p.A. is a digital health company founded in 2020 by Raffaele Petrone and Davide Dettori, with operational headquarters in Turin and Pozzuoli, Italy. The company operates in the digital health sector, focusing on developing artificial intelligence solutions to innovate cancer prevention and diagnostics. Health Triage serves healthcare facilities and medical staff by providing technological tools designed to enhance the quality, precision, and efficiency of diagnostic processes. The firm successfully completed an incubation program at I3P, the Innovative Companies Incubator of Politecnico di Torino. In May 2025, Health Triage secured a €5 million investment from the ENEA Tech and Biomedical Foundation as part of a larger €10 million funding round aimed at advancing its AI-based technologies for early cancer diagnosis.
The company's business model is centered on providing AI-powered software-as-a-service (SaaS) platforms to healthcare providers. Its core offerings target oncology, specifically breast and prostate cancer. One of its flagship products, BreastNegative.ai, is a software platform that assists radiologists in reading mammograms. Given that over 99% of mammograms show no signs of cancer, the system functions as a "first reader," prioritizing potentially problematic cases and, in instances of agreement with the radiologist, can eliminate the need for a second reading, thereby saving time and resources. Another key product is VirtualBiopsy.ai, which offers a non-invasive method for prostate cancer diagnosis. This technology uses AI algorithms and radiomics to assess the presence and aggressiveness of tumors, aiming to reduce the number of invasive biopsies, which have a significant failure rate on the first attempt.
Health Triage is also committed to advancing its AI capabilities through data. The company is developing one of the first data lakes for anonymized and pseudonymized health data to facilitate the continuous improvement of its technologies. This initiative supports its research and development activities and strengthens its collaborations with scientific partners like the Candiolo Cancer Institute, the University of Turin, the Italian Society of Urology (SIU), and the Italian Group for Mammography Screening (GISMa). These partnerships are crucial for the clinical validation of its solutions and for fostering innovation in cancer screening protocols.
Keywords: cancer diagnosis, artificial intelligence, digital health, medical imaging, SaaS, oncology, breast cancer screening, prostate cancer diagnosis, radiomics, clinical decision support, mammography analysis, virtual biopsy, MedTech, health data, precision medicine, diagnostic software, cancer prevention, I3P incubator, ENEA Tech, Davide Dettori, Raffaele Petrone